Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale
Background: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins) improved the diagnosis of Alzheimer’s disease (AD) in research and clinical settings. We previously described the PLM-scale (Paris-Lille-Montpellier study), which combines Aβ42, tau, and phosphorylated ptau(181) biomarke...
Main Authors: | Sylvain Lehmann, Constance Delaby, Guilaine Boursier, Cindy Catteau, Nelly Ginestet, Laurent Tiers, Aleksandra Maceski, Sophie Navucet, Claire Paquet, Julien Dumurgier, Eugeen Vanmechelen, Hugo Vanderstichele, Audrey Gabelle |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-05-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnagi.2018.00138/full |
Similar Items
-
Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
by: Sylvain Lehmann, et al.
Published: (2020-10-01) -
Central nervous system and peripheral inflammatory processes in Alzheimer’s disease: biomarker profiling approach
by: Constance eDELABY, et al.
Published: (2015-08-01) -
Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?
by: Constance Delaby, et al.
Published: (2014-06-01) -
Exacerbated CSF abnormalities in younger patients with Alzheimer's disease
by: Julien Dumurgier, et al.
Published: (2013-06-01) -
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
by: Nicolas R. Barthélemy, et al.
Published: (2020-03-01)